Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5471-5480 Newer>

The Motley Fool February 27, 2009 Brian Orelli	Get a Life, Congress! A Congressional investigation into whether the FDA was right to pull a doctor off of the advisory panel for Eli Lilly's blood thinner prasugrel illustrates why Congress needs to keep its nose out of scientific discussions.
The Motley Fool February 27, 2009 Brian Orelli	When Will Someone Buy Natus Medical? This stock is sporting much lower multiples, waiting for its next big move, and doing everything it can to boost the bottom line.
The Motley Fool February 27, 2009 Brian Orelli	Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government.
The Motley Fool February 27, 2009 Brian Orelli	Double Approvals, Accelerated Growth Genzyme gets a pair of approvals -- one from each side of the Atlantic -- for two different products.
The Motley Fool February 27, 2009 Brian Orelli	Elan's Crash Diet Looks Good Elan needed a makeover, and the new, thinner company is looking better already.
The Motley Fool February 26, 2009 Rich Smith	This Just In: Upgrades and Downgrades RBC Capital Markets initiates coverage on a vast range of medical device and drug makers. Read on for their buys, holds, and one sell.
The Motley Fool February 26, 2009 Brian Orelli	Ranbaxy Spoils It for Everyone The Food and Drug Administration claims that generic-drug maker Ranbaxy falsified data that it submitted to the agency. Other innocent drug companies may suffer from guilt by association.
The Motley Fool February 26, 2009 Robert Steyer	Merck KGaA's Good Chemistry This German conglomerate successfully mixes drugs and chemicals.
The Motley Fool February 25, 2009 Brian Orelli	The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers.
The Motley Fool February 25, 2009 Brian Orelli	Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials.
<Older 5471-5480 Newer> Return to current articles.